Several clinical studies have shown that thrombocytosis is a poor prognostic factor in some types of cancer, but data about the impact of thrombocytosis on prognosis in patients with colon cancer are very limited. We investigated the prevalence and prognostic effect of pre-operative thrombocytosis, defined as a platelet count > 400 3 10 9 /l, retrospectively in patients with node-negative colon cancer. Out of 198 patients, 24 (12.1%) had thrombocytosis, and its presence correlated with tumour depth and lymphatic invasion. Univariate analysis revealed that disease-free survival and overall survival were shorter in patients with pre-operative thrombocytosis than those without thrombocytosis. On multivariate analysis, thrombocytosis alone retained significance as a poor prognostic factor for both disease-free survival and overall survival. In conclusion, this study shows an association between thrombocytosis and poor survival in patients with node-negative colon cancer. The preoperative platelet count may help to identify patients with an unfavourable prognosis in this subgroup.
Introduction
Lymph node involvement is one of the most important prognostic factors in apparently localized carcinoma of the colon and rectum; 1 patients with nodal metastases have a worse outcome than those without nodal metastases. However, recurrent disease occurs in approximately 20 -30% of patients with completely resected node-negative colon cancer (NNCC). 2 Identifying the patients within this subgroup who are at increased risk of tumour recurrence may help to indicate those who would benefit most from adjuvant treatment. The recognition of biological and molecular prognostic factors may allow further insights into the optimal treatment strategy for NNCC. 3 The association between thrombocytosis and malignancy has been known for more than 100 years. 4 Approximately one-third of all cancer patients may have thrombocytosis at the time of diagnosis, 5 and 40% of patients with thrombocytosis may also have a malignancy. 6 Studies assessing the effect of thrombocytosis on prognosis in patients with cancer are very limited, although several recent papers have shown that thrombocytosis is associated with decreased survival in patients with some types of cancers. 7 -10 Although the vast majority of these studies demonstrate that thrombocytosis is a prognostic indicator for outcome, some investigations suggest that it has no prognostic value, and very little has been published about thrombocytosis in patients with colon cancer. 11 In the present study, we investigated the prevalence and prognostic effect of thrombocytosis in patients with NNCC.
Patients and methods

PATIENTS
Patients with NNCC who had undergone primary surgery were included in the study. Clinicopathological data were obtained retrospectively from the patients' medical records. As this was a retrospective study, ethical approval and patient consent were not required.
STATISTICAL ANALYSIS
Patients were divided into two groups on the basis of the pre-operative platelet count: those with a platelet count > 400 × 10 9 /l were considered to have thrombocytosis, in agreement with published criteria.
Disease-free survival (DFS) was measured from the date of diagnosis to the date of first relapse at any site. Overall survival (OS) was measured from the date of diagnosis to the date of death from any cause or to the last follow-up visit.
Spearman's rank correlation was used to test the associations between thrombocytosis and the clinicopathological variables under consideration. Survival probabilities were analysed using the Kaplan-Meier method, and the log-rank test was used to compare survival curves with respect to all the measured variables. The Cox proportional hazards regression model was performed for the evaluation of independent prognostic factors for patient survival. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 198 patients with a median age of 57 years (range 40 -70 years) were included in the study.
At the time of analysis, the median follow-up period of the study population was 47 months (range 19 -100 months). Of the 198 patients, 24 (12.1%) had thrombocytosis. Patient and tumour characteristics are shown in Table 1 . Spearman's rank correlation test revealed that tumour depth, indicated by the pathological category of the tumour (pT), and lymphatic invasion were significantly correlated with thrombocytosis (Table 2 ). There were no significant associations between thrombocytosis and the other factors.
Patients with thrombocytosis had a significantly shorter DFS than patients without thrombocytosis (P = 0.00001, logrank test) ( Fig. 1 ). In patients without thrombocytosis, cumulative survival was 71.5%. In patients with thrombocytosis, the median DFS was 37 months (95% confidence interval [CI] 29 -45 months). There was also a significant difference in OS between the two groups (P = 0.00001, log-rank test) ( Fig. 2 ). In patients with thrombocytosis, the median OS was 50 months (95% CI 37 -63 months), whereas patients without thrombocytosis had a longer OS (cumulative survival was 70.7%).
Univariate analysis indicated that thrombocytosis, tumour depth, grade and lymphatic invasion were all significant predictors of DFS. All these factors remained independent predictors of DFS in multivariate analysis (Table 3) .
Univariate analysis also demonstrated significant associations between OS and thrombocytosis, as well as tumour depth, grade and lymphatic invasion. On multivariate analysis, patients with thrombocytosis, as well as those with a higher pT category, the presence of lymphatic invasion or a higher histological grade, had a significantly reduced OS (Table 4 ).
Discussion
The association between thrombocytosis and malignancy has been well demonstrated.
Thrombocytosis has been described in a variety of solid tumours, including gynaecological, lung, renal, gastric and breast malignancies. 10,12 -15 The prevalence of thrombocytosis in patients with lung cancer has been reported to be 60%, 13 whereas its prevalence in patients with gynaecological cancers was 14 -38%. 12, 16 Thrombocytosis was more common among patients with more advanced disease.
Fewer data are available regarding thrombocytosis in patients with colorectal cancers. Constantini et al. 11 reported that the prevalence of thrombocytosis in patients with colon cancer was 33%. In the present study, 12.1% of patients undergoing surgery for primary colon cancer were found to have a platelet count > 400 × 10 9 /l; the prevalence of thrombocytosis in our patients was low compared with other studies, but our study included only NNCC patients.
Thrombocytosis has been shown to have prognostic significance in patients with gynaecological cancers, renal cell carcinoma and breast cancer. 10, 12, 14 In addition, Monreal et al. 17 the bone marrow by producing thrombopoietic factors that act on megakaryocytes and their precursors. 18 In addition, tumours can initiate intratumoral activation of the coagulation cascade, including platelet activation. 19 Platelets contain thrombopoietin and release it on activation. 20 This plateletreleased thrombopoietin stimulates the bone marrow to generate new platelets and release them into the circulation. Thrombocytosis may adversely affect patient survival because of interactions between platelets and tumour cells. Platelets contain one of the largest stores of angiogenic and mitogenic factors; they may promote tumour cell growth through secreting several angiogenic or tumour growth factors such as platelet-derived endothelial cell growth factor, thrombospondin or vascular endothelial growth factor (VEGF). VEGF, one of the most potent angiogenic cytokines, is expressed by a wide variety of tumours, both in vitro and in vivo. 21 Besides stimulating proliferation of tumour blood vessels, VEGF also increases vascular permeability, possibly contributing to tumour cell extravasation and metastasis formation. 22 In colorectal cancer, serum VEGF correlates with disease stage, and high levels are associated with rapid tumour progression. 23, 24 Unlike other cytokines, VEGF is selective, acting exclusively on vascular endothelial cells. 21, 25 VEGF is also released by platelets on activation. Megakaryocytes have been shown to contain both VEGF mRNA and VEGF protein. 26 VEGF released from activated platelets may play an important role in tumour angiogenesis and metastasis formation.
EG Kandemir, A Mayadagli, B Karagoz et al. Prognostic significance of thrombocytosis in node-negative colon cancer
Platelets also contain several other angiogenic growth factors, including plateletderived endothelial cell growth factor and thrombospondin. 27 Platelet-derived endothelial cell growth factor, which is also known as thymidine phosphorylase, has been shown to be increased in the serum of some patients with cancer compared with healthy controls. 28, 29 Increased expression of thymidine phosphorylase has also been reported in primary colorectal cancer, 30 and studies have shown that this high expression of thymidine phosphorylase was associated with angiogenesis and tumour progression. 31, 32 Thrombospondin, a platelet-secreted protein, is an adhesive glycoprotein that promotes the adhesion of tumour cells to the endothelium, and may potentiate tumour cell metastasis in the presence of a normal clotting system. 33, 34 Platelets also play a role in the sequestration, adherence and penetration of tumour cells through the vascular endothelial barrier, and participate in tumour progression by protecting tumour cells from immune surveillance. 35 In conclusion, the present study shows an association between thrombocytosis and poor survival in patients with NNCC. The pre-operative platelet count may help to identify patients with an unfavourable prognosis in NNCC.
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